“We believe binx is able to follow the way other people think about access to regime tests,” said Matthew Rizzo, OrbiMed partner.
“We are excited about our investment in binx, given its commitment to clinical rigor and its leadership position in the field of sexual fitness in CLIA-exempt contexts,” said Tuan Huyn of ArrowMark.